Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Strongbridge Biopharma Rose as Much as 26.7% Today

By Maxx Chatsko - Aug 8, 2018 at 1:19PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biopharma announced second-quarter 2018 earnings and positive results from a phase 3 study.

What happened

Shares of Strongbridge Biopharma (SBBP) rose nearly 27% today after the company reported second-quarter 2018 earnings results and positive results from a late-stage study. Net product sales from Keveyis, the company's first approved drug, settled at $8.2 million during the first half of the year. Management expects the drug to achieve full-year revenue of $18 million to $20 million. Meanwhile, the company's second approved drug, Macrilen, launched in the United States at the end of July as a treatment for adult growth hormone deficiency.

The tiny biopharma from Ireland also announced positive top-line results for its drug candidate branded as Recorlev, which is being developed as a treatment for endogenous Cushing's syndrome. The disease is marked by abnormalities in the body's ability to manage levels of cortisol, a hormone that regulates stress responses.

As of 12:50 p.m. EDT, the stock had settled to a 13.1% gain.

Five arrows on a chalkboard rising higher.

Image source: Getty Images.

So what

In the first half of 2018 the business reported $8.2 million in revenue and a net loss of $34.8 million. Despite losing more money than in the first half of last year, investors are increasingly optimistic. After all, the rise in administrative expenses was mostly incurred ramping sales of Keveyis and preparing for the launch of Macrilen, while increased research and development expenses are mostly explained by the just-completed phase 3 study for Recorlev.

The positive late-stage results from Recorlev, which has received FDA orphan drug designation making the company think the drug can receive accelerated approval, means the company can have three drugs on the market or preparing for commercialization by the end of 2018. It will still be some time before the business is capable of turning a profit, but the biopharma appears to be firmly on the other side of the risky gauntlet of clinical trials. Plus, with $85.5 million in cash at the end of June, Strongbridge Biopharma is well-positioned to hit the ground running for the commercial activities just ahead.

Now what

Things are humming along for Strongbridge Biopharma right now. The company's approach to treating rare diseases has now been validated with two drug approvals and three positive batches of clinical data in late-stage studies. While the company is flying under Wall Street's radar with a market cap of only $234 million, it could be worth a closer look from biopharma investors, especially if the expanding portfolio of commercial products lives up to its potential.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Strongbridge Biopharma plc Stock Quote
Strongbridge Biopharma plc
SBBP

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
356%
 
S&P 500 Returns
124%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.